Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Investor Presentation (August 2026)
32 slides from Avita Medical's investor presentation, Aug 19, 2026
Slide 1: PermeaDerm I Clinical Study Readout
For personal use only AVITA Medical PermeaDerm I Clinical Study Readout Investor Presentation August 18, 2026
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and uncertainties
Slide 3: Participants
Participants For personal use only Katie Bush, PhD Anju Saraswat, MD Christina Sharon, MD, FACS Senior Vice President, Burn Surgeon, Burn and Acute Care Surgeon, Scientific & Medical Affairs Atrium Health Wake Forest Baton Rouge General AVITA Medical Baptist Burn Center
Slide 4: Three Distinct Technologies. One Purpose.
Three Distinct Technologies. One Purpose. For personal use only 1 PREPARE 2 REBUILD 3 RESTORE PermeaDerm® is a temporary, Cohealyx is a collagen dermal RECELL®, RECELL GO® and biosynthetic wound matrix that matrix that enables vascularization RECELL GO mini convert a small protects and stabilizes th
Slide 5: Temporization Bridges Excision to Definitive Closure
Temporization Bridges Excision to Definitive Closure For personal use only Excise Temporize Close Remove nonviable tissue Patient not ready Autografting Wound bed not ready Donor-skin constrained
Slide 6: Allograft is Considered Standard, But Has Limitations
Allograft is Considered Standard, But Has Limitations1-4 For personal use only Benefits • Proven effective when donor skin is limited • Tolerant of questionable wound beds • Serves as an indicator for graft-readiness Limitations • Frozen storage and thawing requirement • Tissue tracking • Limited si
Slide 7: PermeaDerm Mimics Epidermal Function to Provide Temporary Wound Coverage
PermeaDerm Mimics Epidermal Function to Provide Temporary Wound Coverage For personal use only 1 Outer Silicone Layer O2 Seals the wound bed protecting it from CO2 bacteria & trauma while allowing for gas and exudate exchange 2 Inner Bioactive-coated Nylon Matrix Expedites adherence to wound bed and
Slide 8: PermeaDerm-I Clinical Trial
For personal use only PermeaDerm-I Clinical Trial
Slide 9: Unlocking an Alternative to Allograft
Unlocking an Alternative to Allograft Goal: Establish PermeaDerm as a clinically comparable, For personal use only lower-cost alternative to allograft Study Scope Endpoints ➢ N=40 RCT Safety & Efficacy ➢ ≤30% TBSA, early intervention ➢ Graft take ➢ Healing Weeks 1-8 Skin grafting ➢ Inflammatory prof
Slide 10: U.S. Multicenter Randomized Controlled Trial
U.S. Multicenter Randomized Controlled Trial For personal use only Arizona Burn Center (Dr. Deeter) Ohio State University (Dr. Loftus) Regional One Health (Dr. Hassouba) Atrium Health Wake Forest Baptist (Dr. Saraswat) University of Kansas (Dr. Slater) Grady Health (Dr. Nosanov) Akron Children’s Hos
Slide 11: Primary Endpoint Met: 70% Lower Cost
Primary Endpoint Met: 70% Lower Cost $497.10 For personal use only Mean Cost per % TBSA Treated For every 1% Total Body Surface Area treated, PermeaDerm costs $348.40 less $148.70 p < 0.001* PermeaDerm Allograft N=19 N=21 *P-value is from a one-sided two-sample t-test with 0.025 significance level.
Slide 12: 95.7% Mean Reduction in Preparation Time
95.7% Mean Reduction in Preparation Time For personal use only No Tissue Tracking, Thawing, or Meshing Comparable Affixation Time 14.6 14.4 PermeaDerm PermeaDerm Allograft Allograft PermeaDerm PermeaDerm Mean Time (min) Mean Time (min) Allograft Per 100 cm2 Allograft 3.3 3.5 3.1 1.4 0 0 Obtain Thaw
Slide 13: Strong Healing Outcomes
Strong Healing Outcomes Patients Achieving Patients Achieving For personal use only ≥95% Graft Take Wound Healing 94% 95% 100% 100% Allograft Allograft At Week 1 At Week 8 Wound healing defined as >= 95% re-epithelialization Reference: ClinicalTrials.gov identifier: NCT06750809. Publication in progr
Slide 14: No PermeaDerm-related Safety Concerns
No PermeaDerm-related Safety Concerns PermeaDerm (n=19) Allograft (n=21) For personal use only Events (N) *Subjects (N) Events (N) *Subjects (N) All Adverse Events 7 6 24 12 Study Area 3 3 7 7 Graft Loss 0 0 1 1† Hematoma 0 0 1 1 Infection 1 1 4 4 Tissue Necrosis 1 1 0 0 Pruritus 1 1‡ 0
Slide 15: Strong PermeaDerm Satisfaction Supports Clinical Utility
Strong PermeaDerm Satisfaction Supports Clinical Utility Investigator Satisfaction* Patient Satisfaction* For personal use only 100% 22% 78% 100% 12% 88% satisfied or satisfied or very satisfied very satisfied 0% 0% Neutral, Dissatisfied, or Very Satisfied Satisfied Very Dissatisfied *Asked “How sat
Slide 16: Comparative Case Example
Comparative Case Example PermeaDerm: 59-year-old, female, 364 cm2 , ASA III, lower extremity Allograft: 57-year-old, male, 232 cm2, ASA III, lower extremity For personal use only Excision Placement 2 Days Post-application 01-012 01-001 PermeaDerm Allograft PermeaDerm Allograft PermeaDerm Allograft R
Slide 17: Comparative Case Example
Comparative Case Example PermeaDerm: 59-year-old, female, 364 cm2 , ASA III, lower extremity Allograft: 57-year-old, male, 232 cm2, ASA III, lower extremity For personal use only 8 Week Follow-Up Post-application Removal (Post-autografting) Day 4 Day 5 Day 7 Day 6 PermeaDerm Allograft PermeaDerm All
Slide 18: PermeaDerm Delivered Comparable Clinical Results with Less Workflow Burden & Lower Cost
PermeaDerm Delivered Comparable Clinical Results with Less Workflow Burden & Lower Cost For personal use only Proven • Comparable graft take and healing Clinical • No difference in safety or inflammatory profile Performance • High satisfaction from surgeons & patients • 30 minutes less time: no thaw
Slide 19: Clinical Experience
For personal use only Clinical Experience
Slide 20: Three Distinct Technologies. One Purpose.
Three Distinct Technologies. One Purpose. For personal use only 1 PREPARE 2 REBUILD 3 RESTORE PermeaDerm® is a temporary, Cohealyx is a collagen dermal RECELL®, RECELL GO® and biosynthetic wound matrix that matrix that enables vascularization RECELL GO mini convert a small stabilizes and protects th
Slide 21: Case
For personal use only Case 1
Slide 22: AVITA Medical Portfolio Case #1
AVITA Medical Portfolio Case #1 For personal use only Admission Admission 1 Admitted with 45% TBSA burn wounds; staged surgical plan formulated TBSA: total body surface area Case photos courtesy of Dr. Christina Sharon, MD, FACS (Baton Rouge General)
Slide 23: AVITA Medical Portfolio Case #1
AVITA Medical Portfolio Case #1 For personal use only Post-excision Admission 1 Admitted with 45% TBSA burn wounds; staged surgical plan formulated TBSA: total body surface area Case photos courtesy of Dr. Christina Sharon, MD, FACS (Baton Rouge General)
Slide 24: AVITA Medical Portfolio Case #1
AVITA Medical Portfolio Case #1 3 Days Post-admission For personal use only 1 Admission Admitted with 45% TBSA burn wounds; staged surgical plan formulated 2 PermeaDerm Application For temporary coverage; replaced at 7 days post-admission TBSA: total body surface area Case photos courtesy of Dr. Chr
Slide 25: AVITA Medical Portfolio Case #1
AVITA Medical Portfolio Case #1 71 Days Post-admission For personal use only 1 Admission Admitted with 45% TBSA burn wounds; staged surgical plan formulated 2 PermeaDerm Application For temporary coverage; replaced at 7 days post-admission 3 Cohealyx Application To optimize wound bed 4 Skin Grafting
Slide 26: Case
For personal use only Case 2
Slide 27: AVITA Medical Portfolio Case #2
AVITA Medical Portfolio Case #2 For personal use only 8 Days Post-admission 1 Admission Admitted with 22% TBSA bilateral burns 2 PermeaDerm Application Applied 1-day post-admission for 8 days of temporary coverage TBSA: total body surface area; Case photos courtesy of Dr. Christina Sharon, MD, FACS
Slide 28: AVITA Medical Portfolio Case #2
AVITA Medical Portfolio Case #2 For personal use only 9 Days Post-admission 1 Admission Admitted with 22% TBSA bilateral burns 2 PermeaDerm Application Applied 1 day post-admission for 8 days of temporary coverage 3 Skin Grafting + RECELL For definitive closure; with Cohealyx TBSA: total body surfac
Slide 29: AVITA Medical Portfolio Case #2
AVITA Medical Portfolio Case #2 For personal use only 30 Days Post-admission 1 Admission Admitted with 22% TBSA bilateral burns 2 PermeaDerm Application Applied 1 day post-admission for 8 days of temporary coverage 3 Skin Grafting + RECELL For definitive closure; with Cohealyx Cohealyx Application &
Slide 30: AVITA Medical Portfolio Case #2
AVITA Medical Portfolio Case #2 For personal use only 45 Days Post-admission 1 Admission Admitted with 22% TBSA bilateral burns 2 PermeaDerm Application Applied 1 day post-admission for 8 days of temporary coverage 3 Skin Grafting + RECELL For definitive closure; with Cohealyx Cohealyx Application &
Slide 31: PermeaDerm: An Advanced Alternative to Allograft
PermeaDerm: An Advanced Alternative to Allograft For personal use only Comparable graft take and healing 1 Clinical Confidence No safety concerns Transparent 2 Workflow Simplicity Shorter preparation time Biosynthetic Fits into clinical protocols Wound Matrix 3 Economic Advantage Lower cost than all
Slide 32: Questions?
Questions? For personal use only Katie Bush, PhD Anju Saraswat, MD Christina Sharon, MD, FACS Senior Vice President, Burn Surgeon, Burn and Acute Care Surgeon, Scientific & Medical Affairs Atrium Health Wake Forest Baton Rouge General AVITA Medical Baptist Burn Center ©2026 AVITA Medical. AVITA Medi